Biblio
Export 315 results:
Author Keyword Title Type [ Year
Filters: First Letter Of Title is C [Clear All Filters]
“Can Diet Supplements of Macular Pigment of Lutein, Zeaxanthin, and Meso-zeaxanthin Affect Cognition?”, J Alzheimers Dis, vol. 87, no. 3, pp. 1079-1087, 2022.
, “Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old.”, J Alzheimers Dis, vol. 90, no. 1, pp. 405-417, 2022.
, “Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.”, J Alzheimers Dis, vol. 90, no. 2, pp. 667-680, 2022.
, “Characterization of Mild Cognitive Impairment and Dementia among Community-Dwelling Mexican Americans and Non-Hispanic Whites.”, J Alzheimers Dis, vol. 90, no. 2, pp. 905-915, 2022.
, “Circulating Cell-Free Genomic DNA Is Associated with an Increased Risk of Dementia and with Change in Cognitive and Physical Function.”, J Alzheimers Dis, vol. 89, no. 4, pp. 1233-1240, 2022.
, “Clinical Utility of Cerebrospinal Fluid Aβ42 and Tau Measures in Diagnosing Mild Cognitive Impairment in Early Onset Dementia.”, J Alzheimers Dis, vol. 87, no. 2, pp. 771-780, 2022.
, “Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1585-1603, 2022.
, “Comparative Analysis of Alzheimer's Disease Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and Immunoassay-Based Approach.”, J Alzheimers Dis, vol. 89, no. 1, pp. 193-207, 2022.
, “Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 80, no. 3, pp. 973-977, 2021.
, “Central Obesity, Cardiometabolic Risk, and Cognitive Change in the Study of Latinos: Investigation of Neurocognitive Aging.”, J Alzheimers Dis, vol. 82, no. 3, pp. 1203-1218, 2021.
, “Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 83, no. 1, pp. 179-190, 2021.
, “Cerebrospinal Fluid Proteome Changes in Older Non-Cardiac Surgical Patients with Postoperative Cognitive Dysfunction.”, J Alzheimers Dis, vol. 80, no. 3, pp. 1281-1297, 2021.
, “Cerebrospinal Fluid Sulfatide Levels Lack Diagnostic Utility in the Subcortical Small Vessel Type of Dementia.”, J Alzheimers Dis, vol. 82, no. 2, pp. 781-790, 2021.
, “Cerebrovascular microRNA Expression Profile During Early Development of Alzheimer's Disease in a Mouse Model.”, J Alzheimers Dis, vol. 85, no. 1, pp. 91-113, 2021.
, “Clinical Approach of Low-Dose Whole-Brain Ionizing Radiation Treatment in Alzheimer's Disease Dementia Patients.”, J Alzheimers Dis, vol. 80, no. 3, pp. 941-947, 2021.
, “Clinical Features and Outcomes of Patients with Dementia Compared to an Aging Cohort Hospitalized During the Initial New York City COVID-19 Wave.”, J Alzheimers Dis, vol. 81, no. 2, pp. 679-690, 2021.
, “The Cognition and Flow Study: A Feasibility Randomized Controlled Trial of the Effects of Cognitive Training on Cerebral Blood Flow.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1567-1581, 2021.
, “Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 80, no. 3, pp. 1243-1256, 2021.
, “Cognitive Effects of Aerobic Exercise in Alzheimer's Disease: A Pilot Randomized Controlled Trial.”, J Alzheimers Dis, vol. 80, no. 1, pp. 233-244, 2021.
, “Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial.”, J Alzheimers Dis, vol. 83, no. 4, pp. 1703-1715, 2021.
, “Combining Multimodal Behavioral Data of Gait, Speech, and Drawing for Classification of Alzheimer's Disease and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 84, no. 1, pp. 315-327, 2021.
, “Copper Imbalance in Alzheimer's Disease and Its Link with the Amyloid Hypothesis: Towards a Combined Clinical, Chemical, and Genetic Etiology.”, J Alzheimers Dis, vol. 83, no. 1, pp. 23-41, 2021.
, “Cortical Thickness and Its Association with Clinical Cognitive and Neuroimaging Markers in Cerebral Amyloid Angiopathy.”, J Alzheimers Dis, vol. 81, no. 4, pp. 1663-1671, 2021.
, “A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project.”, J Alzheimers Dis, vol. 83, no. 3, pp. 1149-1159, 2021.
, “Could Altered Evoked Pain Responsiveness Be a Phenotypic Biomarker for Alzheimer's Disease Risk? A Cross-Sectional Analysis of Cognitively Healthy Individuals.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1227-1233, 2021.
,